- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Report from SIR: Cryoablation freezes prostate cancer treatment complications
Focal cryoablation can kill malignant prostate tissue without affecting the urinary system or a man’s sexual potency, according to a study presented at the Society of Interventional Radiology meeting.
Focal cryoablation can kill malignant prostate tissue without affecting the urinary system or a man's sexual potency, according to a study presented at the Society of Interventional Radiology meeting.
Surgery and radiotherapy have shown effectiveness in combating prostate cancer. They treat the whole gland, however, potentially leading to sexual dysfunction and urinary incontinence.
Focal cryoablation, also known as the "male lumpectomy," targets and destroys only malignant tissue, while preserving healthy tissue in and around the prostate, said principal investigator Dr. Gary Onik, director of surgical imaging at the Center for Surgical Advancement at Florida Hospital in Celebration.
Early findings show that focal cryoablation outclasses standard treatment strategies for cancer control, while reducing the risk of complications. Most prostate cancer patients are potential candidates for the procedure, unlike brachytherapy, which is largely confined to low-risk individuals, Onik said.
To date, Onik and colleagues have treated 60 patients using the technique. Preliminary results for 42 patients who have been followed during eight years show that 95% have had stable prostate-specific antigen tests, with no sign of recurrence. Of 32 patients who were potent prior to the procedure, 78% (25) remain potent versus the average 30% with surgery and 50% with radiation therapy. There are no reports of urinary incontinence postcryoablation.
For many patients, incontinence bears far more importance than impotence. Cryoablation can limit this and other complications without compromising cancer control. If long-term studies confirm these findings, the technique has the potential to change the treatment paradigm, Onik said.
For more information from the Diagnostic Imaging archives:
Real-time MR guides liver cryotherapy
Multiple strategies take aim at removing breast lesions
Imaging aims to improve therapeutic balance
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
